RhumbLine Advisers’s Amphastar Pharmaceuticals AMPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.64M | Buy |
83,721
+1,331
| +2% | +$32.6K | ﹤0.01% | 1963 |
|
|
2025
Q4 | $2.21M | Sell |
82,390
-7,739
| -9% | -$199K | ﹤0.01% | 1829 |
|
|
2025
Q3 | $2.4M | Sell |
90,129
-5,158
| -5% | -$133K | ﹤0.01% | 1806 |
|
|
2025
Q2 | $2.19M | Buy |
95,287
+6,329
| +7% | +$157K | ﹤0.01% | 1838 |
|
|
2025
Q1 | $2.58M | Buy |
88,958
+1,631
| +2% | +$52.1K | ﹤0.01% | 1688 |
|
|
2024
Q4 | $3.24M | Buy |
87,327
+1,213
| +1% | +$55.5K | ﹤0.01% | 1635 |
|
|
2024
Q3 | $4.18M | Sell |
86,114
-4,473
| -5% | -$196K | ﹤0.01% | 1522 |
|
|
2024
Q2 | $3.62M | Buy |
90,587
+1,394
| +2% | +$57.8K | ﹤0.01% | 1569 |
|
|
2024
Q1 | $3.92M | Sell |
89,193
-4,547
| -5% | -$235K | ﹤0.01% | 1549 |
|
|
2023
Q4 | $5.8M | Buy |
93,740
+228
| +0.2% | +$12K | 0.01% | 1325 |
|
|
2023
Q3 | $4.3M | Buy |
93,512
+2,559
| +3% | +$140K | 0.01% | 1449 |
|
|
2023
Q2 | $5.23M | Sell |
90,953
-14
| -0% | -$621 | 0.01% | 1346 |
|
|
2023
Q1 | $3.41M | Buy |
90,967
+6,609
| +8% | +$217K | ﹤0.01% | 1541 |
|
|
2022
Q4 | $2.36M | Sell |
84,358
-228
| -0.3% | -$6.62K | ﹤0.01% | 1692 |
|
|
2022
Q3 | $2.38M | Buy |
84,586
+5,399
| +7% | +$176K | ﹤0.01% | 1660 |
|
|
2022
Q2 | $2.75M | Sell |
79,187
-808
| -1% | -$28.8K | ﹤0.01% | 1589 |
|
|
2022
Q1 | $2.87M | Buy |
79,995
+2,019
| +3% | +$57.3K | ﹤0.01% | 1623 |
|
|
2021
Q4 | $1.82M | Sell |
77,976
-450
| -0.6% | -$9.2K | ﹤0.01% | 1941 |
|
|
2021
Q3 | $1.49M | Sell |
78,426
-12,900
| -14% | -$253K | ﹤0.01% | 2047 |
|
|
2021
Q2 | $1.84M | Buy |
91,326
+7,070
| +8% | +$133K | ﹤0.01% | 1991 |
|
|
2021
Q1 | $1.54M | Buy |
84,256
+1,675
| +2% | +$31.1K | ﹤0.01% | 2016 |
|
|
2020
Q4 | $1.66M | Sell |
82,581
-1
| -0% | -$19 | ﹤0.01% | 1932 |
|
|
2020
Q3 | $1.55M | Sell |
82,582
-5,050
| -6% | -$102K | ﹤0.01% | 1811 |
|
|
2020
Q2 | $1.97M | Sell |
87,632
-5,727
| -6% | -$105K | ﹤0.01% | 1738 |
|
|
2020
Q1 | $1.39M | Sell |
93,359
-21,151
| -18% | -$368K | ﹤0.01% | 1739 |
|
|
2019
Q4 | $2.21M | Buy |
114,510
+5,579
| +5% | +$107K | ﹤0.01% | 1748 |
|
|
2019
Q3 | $2.16M | Buy |
108,931
+1,358
| +1% | +$28.3K | ﹤0.01% | 1704 |
|
|
2019
Q2 | $2.27M | Buy |
107,573
+1,453
| +1% | +$30.4K | ﹤0.01% | 1663 |
|
|
2019
Q1 | $2.17M | Buy |
106,120
+2,177
| +2% | +$48.8K | ﹤0.01% | 1658 |
|
|
2018
Q4 | $2.07M | Buy |
103,943
+16,080
| +18% | +$317K | ﹤0.01% | 1624 |
|
|
2018
Q3 | $1.69M | Sell |
87,863
-1,480
| -2% | -$26.4K | ﹤0.01% | 1746 |
|
|
2018
Q2 | $1.36M | Buy |
89,343
+6,191
| +7% | +$108K | ﹤0.01% | 1875 |
|
|
2018
Q1 | $1.56M | Buy |
83,152
+2,464
| +3% | +$46.3K | ﹤0.01% | 1734 |
|
|
2017
Q4 | $1.55M | Buy |
80,688
+9,455
| +13% | +$177K | ﹤0.01% | 1757 |
|
|
2017
Q3 | $1.27M | Buy |
71,233
+1,470
| +2% | +$24.2K | ﹤0.01% | 1860 |
|
|
2017
Q2 | $1.25M | Buy |
69,763
+1,925
| +3% | +$30.5K | ﹤0.01% | 1841 |
|
|
2017
Q1 | $984K | Buy |
67,838
+20,764
| +44% | +$326K | ﹤0.01% | 1920 |
|
|
2016
Q4 | $867K | Buy |
47,074
+3,071
| +7% | +$59.7K | ﹤0.01% | 1931 |
|
|
2016
Q3 | $835K | Buy |
44,003
+9,440
| +27% | +$171K | ﹤0.01% | 1919 |
|
|
2016
Q2 | $557K | Sell |
34,563
-1,722
| -5% | -$24.3K | ﹤0.01% | 2129 |
|
|
2016
Q1 | $435K | Buy |
36,285
+1,495
| +4% | +$17.6K | ﹤0.01% | 2313 |
|
|
2015
Q4 | $495K | Buy |
34,790
+2,385
| +7% | +$31.5K | ﹤0.01% | 2242 |
|
|
2015
Q3 | $379K | Buy |
32,405
+1,725
| +6% | +$25.9K | ﹤0.01% | 2404 |
|
|
2015
Q2 | $539K | Buy |
+30,680
| New | +$478K | ﹤0.01% | 2275 |
|
Other funds holding AMPH
VCM
BTW
RhumbLine Advisers's AMPH Position: Q1 2026 in Review
RhumbLine Advisers increased its Amphastar Pharmaceuticals (AMPH) stake by 1.6% in Q1 2026, buying an estimated $32.6K and bringing the position to 83,721 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1963.
RhumbLine Advisers first reported a position in AMPH in Q2 2015 and has held it in 44 quarters since. The position peaked at $5.8M in Q4 2023. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.
- RhumbLine Advisers held 83,721 shares of Amphastar Pharmaceuticals worth $1.64M as of Q1 2026.
- RhumbLine Advisers bought 1,331 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $32.6K.
- Amphastar Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1963 holding.
- RhumbLine Advisers first reported a position in Amphastar Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
- RhumbLine Advisers's Amphastar Pharmaceuticals position peaked at $5.8M in Q4 2023.
- 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.